The relationship between biofilm formation and mortality in patients with Candida tropicalis candidemia

Microb Pathog. 2021 Jun:155:104889. doi: 10.1016/j.micpath.2021.104889. Epub 2021 Apr 18.

Abstract

Background: Biofilm formation by Candida species is an influential virulence factor in candidemia pathogenesis. We investigated the relationship between biofilm formation of Candida tropicalis isolates with the clinical characteristics and mortality outcomes in patients with candidemia.

Materials and methods: Thirty-nine C. tropicalis isolates were recovered from patients with candidemia admitted to two university hospitals in Tehran, Iran. Biofilm mass and metabolic activity of C. tropicalis biofilms were assessed in vitro with two colorimetric methods. The sessile minimum inhibitory concentrations (SMICs) were evaluated in vitro by treating preformed biofilms with diluted concentrations of azoles according to CLSI-M27 A3/S4 protocol, followed by metabolic activity quantification. The expressions of ERG11, UPC2, MDR1, and CDR1 genes were also evaluated.

Results: All C. tropicalis isolates produced biofilm. Respectively, higher <7-day and ≥7-day mortality rates were found among cases with high metabolic activity (46.7% vs. 13%, P = 0.03) and high biofilm mass (31.8% vs. 0, P = 0.029). Sessile cells had high resistance to fluconazole, voriconazole, and itraconazole. The azole minimum inhibitory concentrations (MICs) of C. tropicalis sessile were significantly greater than the planktonic minimum inhibitory concentrations (PMICs). In fluconazole-treated biofilms, the expression of ERG11 and UPC2 genes was increased.

Conclusion: Our findings highlight the importance of C. tropicalis biofilm formation as an important factor in candidemia pathogenesis and the clinical outcome of patients with candidemia.

Keywords: Azole resistance; Biofilm; Candida tropicalis; Candidemia; Mortality.

MeSH terms

  • Antifungal Agents / pharmacology
  • Biofilms
  • Candida tropicalis* / genetics
  • Candidemia*
  • Drug Resistance, Fungal
  • Fluconazole / pharmacology
  • Humans
  • Iran
  • Microbial Sensitivity Tests

Substances

  • Antifungal Agents
  • Fluconazole